A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a day to control the symptoms of manic phase of bipolar disorder.
18 Years - 65 Years
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Mar 2012 by AstraZeneca Pharmaceuticals
No locations available
|Experimental: Quetapine 600 mg|
Drug: Quetiapine 600mg
300 mg quetiapine fumarate tablets for oral use. Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day.